Cortexyme, Inc. (CRTX) |
| 1.95 0.05 (2.63%) 08-01 00:00 |
| Open: | 1.91 |
| High: | 1.97 |
| Low: | 1.86 |
| Volume: | 272,208 |
| Market Cap: | 70(M) |
| PE Ratio: | -0.66 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.30 |
| Resistance 1: | 1.97 |
| Pivot price: | 1.95 |
| Support 1: | 1.90 |
| Support 2: | 1.86 |
| 52w High: | |
| 52w Low: |
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Financials
| EPS | -2.963 |
| Book Value | 3.530 |
| PEG Ratio | -0.04 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -37.5 |
| Return on Equity (ttm) | -67.3 |
Company news
Fri, 10 Oct 2025
Cortexyme (NASDAQ:CRTX) Share Price Passes Above 200 Day Moving Average - What's Next? - MarketBeat
Fri, 20 May 2022
Cortexyme Announces Completion Of Novosteo Acquisition - RTTNews
Mon, 14 Feb 2022
User - FinancialContent
Thu, 03 Feb 2022
Alzheimer's drug company to cut workforce in half, pay off exiting execs - The Business Journals
Tue, 01 Feb 2022
After Alzheimer's drug flop, Peninsula biotech's founding execs exit - The Business Journals
Wed, 01 Dec 2021
2 Stocks With Short Squeeze Potential In December - TheStreet
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
